Site Search
Professionals 77 results
- Julie Goodman
- Chief Corporate Social Responsibility Officer
- +1 312-558-7535
- vCard
Chief Corporate Social Responsibility Officer
Capabilities 21 results
Practice Area
Environmental, Social & Governance (ESG)
Winston’s Environmental, Social, & Governance (ESG) Advisory Team synthesizes the firm’s multidisciplinary experience to help boards, management teams, and investors oversee the complete spectrum of ESG-related legal and business issues.
Practice Area
Winston’s Environmental Practice brings decades of experience to our clients. Chaired by Eleni Kouimelis, former assistant regional counsel with USEPA Region 5, our Environmental Practice provides comprehensive services to clients around the globe.
Industry
As core segments of the global economy continue to embrace sustainable and carbon-neutral energy resources as complementary and integral to fossil-based systems of energy production and consumption, we stand ready to guide our clients through the energy transition. Our team is at the forefront of the flourishing energy transition market, and we bring practical experience, perspective, and innovative thinking to the sector. By combining our more than 40 years of experience in renewable and conventional energy with an integrated service approach, we help clients to plan for, invest in, and thrive in today’s shifting environment. Not only does our team include experienced energy and corporate lawyers, but also practitioners with deep experience in tax credits and tax equity, project finance, infrastructure, and power and renewables to serve the varied needs of our client base.
Experience 22 results
Experience
|December 23, 2024
Winston advises Atlantic Sustainable Catch in its acquisition of Atlantic Capes Fisheries
Experience
|June 26, 2024
Winston Represented Hayward Holdings in its Acquisition of ChlorKing
Insights & News 247 results
Client Alert
|May 1, 2025
|3 Min Read
April 2025 Executive Order Targets Prescription Drug Price Reduction
On April 15, 2025, President Trump signed an executive order titled “Lowering Drug Prices by Once Again Putting Americans First.” The subject matter of this executive order criss-crosses considerable policy ground in the overall U.S. pharmaceutical distribution chain. The executive order sets forth the administration’s statement of objectives to reduce prescription medication costs by promoting competition and eliminating practices that lead to high drug prices. Referencing regulatory and policy actions from the first Trump administration and the Biden administration’s policy steps, including the Inflation Reduction Act of 2022 aimed at lowering prescription drug prices for Medicare beneficiaries, the executive order sets forth a broad agenda to impact Medicare prescription drug costs, including in the Medicare Part D program.[1] The order directs the Secretary of Health and Human Services (HHS) to propose and seek comment on guidance for the Medicare Drug Price Negotiation Program and collaborate with Congress to align the treatment of small molecule drugs with biological products, citing concerns about industry investment distortions and cost increases for Medicare and its beneficiaries.[2]
Client Alert
|April 29, 2025
|6 Min Read
The Path to PISCES - Key Milestones for the UK's First Private Securities Trading System
The UK is establishing the Private Intermittent Securities and Capital Exchange System (PISCES), a new platform for private companies to trade their securities, the key features of which are outlined in our previous client alert, “The Close of the PISCES Consultation Period – An Opportunity for Private Market Growth”.
Competition Corner
|April 25, 2025
|4 Min Read
Spotlight on Japan: Comparative Developments in Business and Human Rights Regulations
In recent years, the international community has increasingly focused on the importance of respecting human rights in corporate activities. This trend was driven in part by the United Nations’ adoption of the Guiding Principles on Business and Human Rights in 2011, which accelerated the global movement towards holding companies accountable for human rights violations.
Other Results 17 results
Site Content
ESG in finance can refer to, among other things, financing tools such as Green, Social, and Sustainability Bonds and similar ESG-related debt instruments, as well as the separate discipline of ESG Investing. ESG stands for Environmental, Social, and Governance. Investors are increasingly applying these non-financial factors as part of their analysis to identify ESG-related risks and opportunities in particular investments. ESG metrics have not historically been included in financial reporting, though companies are increasingly making disclosures in their annual report or in a standalone sustainability report, and regulatory requirements for such disclosures, including from the SEC, are expanding.
Site Content
Greenwashing is the act of making false, misleading, or exaggerated claims about an entity’s environmental or sustainability record or practices, including the environmental impact of operations, products, or services. Greenwashing reflects a gap between the symbolic and substantive action taken by a company or product in order to gain an environmentally friendly image. For example, greenwashing occurs when a company spends time and money advertising goods or services as environmentally friendly, closer to nature, or otherwise “green,” when the impact on the environment is not materially distinct from other comparable goods or services.
Law Glossary
What Is Corporate Social Responsibility (CSR)?
Corporate Social Responsibility (CSR) is a broad management concept whereby practices and policies are undertaken by corporations as a part of corporate governance with the intention of having a positive influence on the world by pursuing pro-social objectives in addition to maximizing profits. CSR, also called corporate citizenship in some contexts, may be pursued or enhanced through social-driven programs, such as philanthropy, volunteer, and conservation efforts.